Loading
Every dated change on the records linked to Endometrial cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum
ORR 55.
A milestone in how this cancer is treated.
Primary advanced/recurrent endometrial cancer with chemotherapy (all-comers)
A milestone in how this cancer is treated.
Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer
Endometrial ORR 57.
PFS HR 0.
PFS HR 0.
OS 44.
Three trials in one year; dostarlimab approved for dMMR (July 2023).
A milestone in how this cancer is treated.
dMMR recurrent/advanced endometrial cancer; dMMR solid tumours
Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab
Companion diagnostic for dostarlimab in dMMR endometrial cancer
OS 18.
A milestone in how this cancer is treated.
POLE-ultramutated, MSI-hypermutated, copy-number low, copy-number high (p53-abnormal).
A milestone in how this cancer is treated.
Vaginal brachytherapy gave similar vaginal control and survival to external beam radiotherapy with less gastrointestinal toxicity.
A milestone in how this cancer is treated.
Palliative treatment of advanced endometrial and breast cancer (megestrol)
A milestone in how this cancer is treated.